Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company developing cancer therapies, has announced its participation in two major investor conferences in December 2024. The company will attend the Evercore 7th Annual HealthCONx Conference in Coral Gables, FL on December 3rd, featuring a fireside chat at 7:55 a.m. ET and one-on-one meetings. Additionally, Arcus will participate in the Citi 2024 Global Healthcare Conference in Miami, FL on December 4th for one-on-one meetings only. Live webcasts and replays will be available on the company's website.
Arcus Biosciences (NYSE:RCUS), un'azienda biofarmaceutica in fase clinica che sviluppa terapie per il cancro, ha annunciato la sua partecipazione a due importanti conferenze per investitori nel dicembre 2024. L'azienda parteciperà alla 7ª Conferenza Annuale HealthCONx di Evercore a Coral Gables, FL, il 3 dicembre, con una chiacchierata informale alle 7:55 a.m. ET e incontri one-to-one. Inoltre, Arcus parteciperà solo a incontri one-to-one alla Conferenza Globale Sanitaria di Citi 2024 a Miami, FL, il 4 dicembre. Saranno disponibili webcast dal vivo e repliche sul sito web dell'azienda.
Arcus Biosciences (NYSE:RCUS), una empresa biofarmacéutica en etapa clínica que desarrolla terapias contra el cáncer, ha anunciado su participación en dos conferencias importantes para inversores en diciembre de 2024. La empresa asistirá a la 7ª Conferencia Anual HealthCONx de Evercore en Coral Gables, FL, el 3 de diciembre, con una charla informal a las 7:55 a.m. ET y reuniones uno a uno. Además, Arcus participará solo en reuniones uno a uno en la Conferencia Global de Salud Citi 2024 en Miami, FL, el 4 de diciembre. Se dispondrán de retransmisiones en vivo y repeticiones en el sitio web de la empresa.
Arcus Biosciences (NYSE:RCUS), 암 치료제를 개발하는 임상 단계의 생물 제약 회사가 2024년 12월 두 가지 주요 투자자 회의에 참석한다고 발표했습니다. 이 회사는 12월 3일 플로리다주 코랄게이블스에서 열리는 Evercore 제7회 연례 HealthCONx 회의에 참석하며, 오전 7:55(동부 표준시)에 진행되는 대화식 채팅과 일대일 회의를 가집니다. 이어서 Arcus는 12월 4일 플로리다주 마이애미에서 열리는 Citi 2024 글로벌 헬스케어 회의에 일대일 회의만으로 참여할 예정입니다. 라이브 웹캐스트 및 재생이 회사 웹사이트에서 제공될 것입니다.
Arcus Biosciences (NYSE:RCUS), une entreprise biopharmaceutique en phase clinique développant des thérapies contre le cancer, a annoncé sa participation à deux grandes conférences pour investisseurs en décembre 2024. L'entreprise assistera à la 7ème Conférence Annuelle HealthCONx d'Evercore à Coral Gables, FL, le 3 décembre, avec une discussion informelle à 7h55 ET et des réunions individuelles. De plus, Arcus participera uniquement à des réunions individuelles à la Conférence Mondiale de la Santé Citi 2024 à Miami, FL, le 4 décembre. Des webcasts en direct et des rediffusions seront disponibles sur le site web de l'entreprise.
Arcus Biosciences (NYSE:RCUS), ein biopharmazeutisches Unternehmen in klinischer Phase, das Krebstherapien entwickelt, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Dezember 2024 angekündigt. Das Unternehmen wird am 3. Dezember an der 7. jährlichen HealthCONx-Konferenz von Evercore in Coral Gables, FL, teilnehmen, die um 7:55 Uhr ET mit einem informellen Gespräch beginnt und Einzelgespräche ermöglicht. Darüber hinaus wird Arcus nur an Einzelgesprächen auf der Citi 2024 Global Healthcare Conference in Miami, FL, am 4. Dezember teilnehmen. Live-Webcasts und Wiederholungen werden auf der Website des Unternehmens verfügbar sein.
- None.
- None.
Evercore 7th Annual HealthCONx Conference
Date: Tuesday, December 3rd, 2024
Location:
Format: Fireside chat & 1x1 meetings
Time: 7:55 a.m. ET
Citi 2024 Global Healthcare Conference
Date: Wednesday, December 4th, 2024
Location:
Format: 1x1 meetings only
Live webcasts of the fireside chats and panel will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. Replays will be available following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, dual A2a/A2b receptor, CD39 and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241119104778/en/
Investor Inquiries
Pia Eaves (Banerjee)
Head of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com
Media Inquiries
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Source: Arcus Biosciences
FAQ
When is Arcus Biosciences (RCUS) presenting at the Evercore HealthCONx Conference in 2024?
Which investor conferences will Arcus Biosciences (RCUS) attend in December 2024?
Where can investors watch Arcus Biosciences (RCUS) conference presentations?
